for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Natco Pharma Ltd.

NATP.NS

Latest Trade

815.40INR

Change

-14.80(-1.78%)

Volume

44,260

Today's Range

810.60

 - 

837.50

52 Week Range

771.50

 - 

1,189.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
830.20
Open
837.50
Volume
44,260
3M AVG Volume
5.29
Today's High
837.50
Today's Low
810.60
52 Week High
1,189.00
52 Week Low
771.50
Shares Out (MIL)
182.34
Market Cap (MIL)
153,592.30
Forward P/E
31.04
Dividend (Yield %)
0.71

Next Event

Q2 2022 Natco Pharma Ltd Earnings Release

Latest Developments

More

India's Natco Pharma June-Quarter Consol Net Profit Falls

Natco Pharma Gets Approval For Carfilzomib Vials ANDA (Generic For KYPROLIS) In U.S. Market

Natco Pharma Gets Emergency Use Nod For Baricitinib Tablets For COVID-19 Treatment

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Natco Pharma Ltd.

Natco Pharma Limited is a pharmaceutical company. The Company is engaged in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The Company's segments include active pharmaceuticals ingredient, finished dosage formulations, job works, pharmacy and others. The Company's product categories include Domestic Formulations, International Formulations, API's and Blockbusters. The Company's products include Alphalan, Bandrone, Bendit, Clokeran, Lenalid, Thioplan, Anastronat, Capnat, Fulvenat, Kabanat, Natdox-LP, Rapact, Temonat, X-Trant, Glatimer, Hepcinat, Natdac, Natzold, Tigi, Alprazolam, Chloroquine Phosphate, Lansoprazole, Letrozole, Granisetron, Rizatriptan IR, Imatinib, Salmeterol Xinafoate, Sertraline Form I, Ibandronate Sodium Monohydrate, Pantoprazole Sodium Sesquihydrate, Ondansetron Hydrochloride (Injectable Grade), Daclatasvir and Glatiramer Acetate. The Company manufactures over 20 products under contract.

Industry

Biotechnology & Drugs

Contact Info

Natco House, Road No 2, Banjara Hills

500034

India

+91.40.23547532

http://www.natcopharma.co.in/

Executive Leadership

V. C. Nannapaneni

Executive Chairman of the board, Managing Director

Rajeev Nannapaneni

Executive Vice Chairman of the Board, Chief Executive Officer

S. V. V. N. Appa Rao

Chief Financial Officer, Vice President - Finance and Accounts

Linga Rao

President - Technical Affairs, Director

P. S. R. K. Prasad

Executive Vice President - Corporate Engineering Services, Additional Wholetime Director

Key Stats

2.75 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2019

20.9K

2020

19.2K

2021

20.5K

2022(E)

22.0K
EPS (INR)

2019

34.870

2020

25.260

2021

24.160

2022(E)

27.138
Price To Earnings (TTM)
39.11
Price To Sales (TTM)
8.09
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
29.65
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

AbbVie, J&J units' Imbruvica patents upheld by Delaware court

AbbVie's Pharmacyclics LLC and Johnson & Johnson's Janssen Biotech on Thursday won a ruling in Delaware federal court that four patents related to their blockbuster cancer drug Imbruvica are valid, in a dispute against two other pharmaceutical companies over a proposed generic...

BRIEF-Natco Pharma Donating Chloroquine Phosphate Tablets For Columbia University's Trial

* DONATING CHLOROQUINE PHOSPHATE TABLETS, THROUGH U.S. MARKETING PARTNER, TO COLUMBIA UNIVERSITY

BRIEF-Natco Pharma Ltd's Vizag Formulation Facility Gets U.S. FDA Approval

* VIZAG FORMULATION FACILITY RECEIVES USFDA APPROVAL Source text for Eikon: Further company coverage:

BRIEF-FDA Completes Inspection Of India's Natco Pharma's Kothur Formulation Facility

* U.S. FDA COMPLETES INSPECTION OF NATCO'S KOTHUR FORMULATION FACILITY

BRIEF-India's Natco Pharma Dec Quarter Consol Profit Falls

* DEC QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES VERSUS 1.6 BILLION RUPEES YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up